Shares of KalVista Pharmaceuticals climbed after the company said it saw strong demand for Ekterly, a treatment for a rare genetic disorder, in its latest quarter. The stock rose 14%, to $17.99, in ...
Stocktwits on MSN
KalVista Pharmaceuticals stock rallies after hours on strong genetic disorder drug sales kickstart
KalVista launched Ekterly in the U.S. in July for the treatment of acute attacks of hereditary angioedema in adults and ...
Morning Overview on MSN
Brazilian arthritis folk cure tested, and the data looks promising
For generations, Brazilians have turned to a colorful garden plant to soothe aching joints, trusting experience long before ...
Multiple milestones anticipated from late-stage portfolio including topline results from DIAMOND Phase 3 trials with OCS-01 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback